Brazil speeds up approval process for generics and biologicals

Home/Guidelines | Posted 06/06/2014 post-comment0

Brazil’s National Health Surveillance Agency [Agência Nacional de Vigilância Sanitária, ANVISA] announced on 3 June 2014 the publication of a new guideline for generics and biologicals aimed at speeding up the regulatory procedure.

Brazil flag V13C03

The new guideline (RDC 31/29 May 2014) provides for a simplified procedure for requests for registration, post-registration and renewal of registration of generic, similar (medicamentos similares), specific*, energized#, herbal and biological drugs.

ANVISA estimates that the new procedures will reduce the time to registration in Brazil by approximately 30%. Companies wishing to apply for registration of medicines in accordance with the new regulation may do so exclusively via electronic application, as of 4 June 2014.

ANVISA and the Brazilian Government have several initiatives ongoing to improve the availability of medicines to the Brazilian population. ANVISA recently proposed that 'medicamentos similares' should be interchangeable with their reference drug in the same way as generics are, thereby reducing their cost; generics must be priced 35% lower than the reference product category [1]. While the Brazilian Government has proposed that medicines be exempt from tax [2].

*Specific drugs are products that do not fit into other categories and cannot be tested for bioequivalence against a reference drug.

#Energized drugs are preparations from substances that are subjected to successive dilutions, that are administered as homeopathic, anthroposophic or homotoxicological therapy.

Editor’s comment

If you would like to receive a copy* of the guideline, please send us an email.

*For profit organizations subjected to a fee

Related articles

Confusion exists in Brazil over generics

Brazilian guidelines for follow-on biological products

References

1. GaBI Online - Generics and Biosimilars Initiative. Brazil to designate medicamentos similares as interchangeable [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 6]. Available from: www.gabionline.net/Policies-Legislation/Brazil-to-designate-medicamentos-similares-as-interchangeable

2. GaBI Online - Generics and Biosimilars Initiative. Proposal in Brazil to exempt medicines from tax [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 6]. Available from: www.gabionline.net/Policies-Legislation/Proposal-in-Brazil-to-exempt-medicines-from-tax

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2012 Pro Pharma Communications International. All Rights Reserved.

Source: ANVISA

Related content
FDA updates generics guidance due to COVID-19 pandemic
34 AA010660
Home/Guidelines Posted 01/10/2021
WHO guidelines on pharmaceutical pricing policies
Pay for Delay DrugsMoneyGeneric V13F21
Home/Guidelines Posted 24/09/2021
Mexico introduces new decree on health regulation
Regulation-V13H16
Home/Guidelines Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010